• Home
  • News

Sichenzia Ross Ference LLP Represents Equillium, Inc. in $150 Million At-The-Market Offering Through Jeffries LLC 

equilliam logo

Press Release – New York, NY – July 16, 2020 – Sichenzia Ross Ference LLP announced that it represented Equillium, Inc. (NASDAQ: “EQ”), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, in an At-The-Market Offering (“ATM”), whereby Equillium may sell up to $150 million of common stock from time-to-time.  Jefferies LLC is acting as the sales agent in connection with the ATM.

The shares were registered on Equillium’s Registration Statement on Form S-3 declared effective by the U.S. Securities and Exchange Commission on November 25, 2019 (File No. 333-234683) and the prospectus supplement relating to the ATM dated July 14, 2020.

The Sichenzia Ross Ference LLP team was led by partners Marc J. Ross and James M. Turner.

Sichenzia Ross Ference Carmel LLP